Full Press Release Details
< Medical Publications and Presentations
Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002
52nd Child Neurology Society Annual Meeting - 10/06/2023
Download PDF
Download PDF
ZVRA Positive Sentiment
Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002
Key Takeaway: The article discusses the long-term effects of Arimoclomol in treating Niemann-Pick disease type C (NPC), presenting data from a 48-month study (CT-ORZY-NPC-002). This evaluation was showcased at the 52nd Child Neurology Society Annual Meeting, indicating the ongoing research and interest in NPC therapies.
Price reaction · baseline $4.6362 (2023-10-04T16:07:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
- Long-term data from the study shows promising results.
- Presentation at a reputable annual meeting highlights its significance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Frequently Asked Questions
What is the focus of the study on Arimoclomol?
The study evaluates the long-term effects of Arimoclomol in treating Niemann-Pick disease type C.
Where was the Arimoclomol data presented?
The data was presented at the 52nd Child Neurology Society Annual Meeting.
How long was the Arimoclomol study conducted?
The study was conducted over a period of 48 months.
What is the significance of the CT-ORZY-NPC-002 study?
It provides important insights into the long-term efficacy of Arimoclomol for NPC.